United States|
LDN 193189 Hydrochloride
(CAS: 1062368-62-0) |
| SKU-Pack Size | Availability | Size | Price | |
| EBC51016-1ML | In Stock | 1mL(10mM in DMSO) | $223.50 | |
| EBC51037-1MG | In Stock | 1mg | $73.50 | |
| EBC51038-5MG | In Stock | 5mg | $133.50 | |
| EBC51038-10MG | In Stock | 10mg | $208.50 | |
| EBC51037-25MG | In Stock | 25mg | $373.50 |
| Please Select The Country You Are In To Find Your Local Distributor. |
| EbioCell | Phone:(540) 808-3925 | |
| Imperial Business Park 4819 Emperor Boulevard, | E-mail:order@ebiocell.com | |
| United States | Suite 408 Durham, NC 27703, USA | Web:www.ebiocell.com |
| Product Information | |||||||||||||||||||||
| Synonym(s) | LDN-193189 hydrochloride, LDN193189 HCl | ||||||||||||||||||||
| Chemical Name | 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | ||||||||||||||||||||
| Application | LDN 193189 HCl is a selective BMP signaling inhibitor | ||||||||||||||||||||
| CAS Number | 1062368-62-0 | ||||||||||||||||||||
| Purity | ≥98.0% | ||||||||||||||||||||
| Molecular Weight | 442.94 | ||||||||||||||||||||
| Molecular Formula | C₂₅H₂₂N₆ HCl | ||||||||||||||||||||
| SMILES | C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3.Cl | ||||||||||||||||||||
| Target & IC50 | ALK2: IC50 = 5 nM ALK3: IC50 = 30 nM |
||||||||||||||||||||
| Solubility | DMSO: 55.23mg/ml (100 mM) | ||||||||||||||||||||
| Preparing Stock Solutions |
|
||||||||||||||||||||
| Shipping | Gel Pack | ||||||||||||||||||||
| Storage | Store at -20°C | ||||||||||||||||||||
| Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. | ||||||||||||||||||||
| Product Description | |
LDN193189 is a dorsomorphin derivative and potent BMP pathway inhibitor. It is reported to inhibit bone morphogenetic protein (BMP) type I receptors ALK1, ALK2, ALK3, and ALK6. LDN193189 is useful for the promotion of specific cell differentiation and the study of ectopic ossification. The salt-based form of LDN193189 has higher solubility in DMSO than LDN193189 |
| Specific Protocols | |